C7抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse lung tissue lysate, Primary antibody: P09416(C7 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 minutes    

  
  

The C7 antibody targets complement component 7 (C7), a critical protein in the complement system’s terminal pathway. C7. a 150-kDa glycoprotein, binds to the C5b-6 complex during immune responses, enabling the assembly of the membrane attack complex (MAC). MAC formation induces pore-like structures on pathogen surfaces or aberrant host cells, leading to lysis and clearance. Dysregulation of MAC activity is implicated in diseases like paroxysmal nocturnal hemoglobinuria (PNH), age-related macular degeneration (AMD), and certain autoimmune disorders.

C7-specific antibodies are explored for therapeutic intervention to block excessive MAC-mediated damage. Unlike upstream inhibitors (e.g., anti-C5 therapies like eculizumab), targeting C7 may preserve early complement functions (e.g., opsonization, inflammation modulation) while mitigating downstream pathological effects. This approach could reduce side effects, such as infection risks linked to broad complement suppression.

Research on C7 antibodies also extends to diagnostic applications, identifying C7 deficiencies or mutations associated with increased susceptibility to bacterial infections. Current studies focus on monoclonal antibody development, preclinical efficacy, and safety profiling. Challenges include ensuring specificity and optimizing pharmacokinetics. Overall, C7 antibodies represent a promising, targeted strategy for complement-mediated diseases, balancing therapeutic precision with immune system functionality. Further clinical validation is needed to define their role in treatment paradigms.

(Word count: 247)